Johnson & Johnson

11/23/2021 | Press release | Distributed by Public on 11/23/2021 08:29

European Commission Approves BYANNLI® (6-monthly Paliperidone Palmitate; PP6M) for the Maintenance Treatment of Schizophrenia in Adults